LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Open

SectorHealthcare

14.47 -0.89

Buy Sell

Overview

Share price change

24h

Current

Min

14.47

Max

15.05

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.725 108.767
Profit margin	163.843
Employees	1,780
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+45.02% upside

Market Stats
By TradingEconomics
Market Cap	2.7B
Previous open	15.36
Previous close	14.47

News Sentiment

By Acuity

50%

161 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 lut 2026, 23:07 UTC

Earnings

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 23:01 UTC

Earnings

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:59 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 lut 2026, 22:42 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 lut 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 lut 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 lut 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 lut 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24 lut 2026, 23:16 UTC

Earnings

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 lut 2026, 23:13 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 lut 2026, 23:12 UTC

Earnings

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 lut 2026, 23:08 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 lut 2026, 23:07 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 lut 2026, 22:52 UTC

Earnings

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 22:46 UTC

Earnings

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Warner Receives New Bid From Paramount -- 3rd Update

24 lut 2026, 22:29 UTC

Earnings

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 lut 2026, 22:28 UTC

Earnings

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 lut 2026, 22:25 UTC

Earnings

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 lut 2026, 22:24 UTC

Earnings

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 lut 2026, 22:23 UTC

Earnings

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 lut 2026, 22:22 UTC

Earnings

Woolworths Interim Dividend 45 Australian Cents/Share

24 lut 2026, 22:22 UTC

Earnings

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 lut 2026, 22:21 UTC

Earnings

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

45.02% upside

12 Months Forecast

Average 22 USD 45.02%

High 22 USD

Low 22 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

161 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.